Drug intelligence / Profile preview

vonoprazan fumarate + furazolidone + doxycycline

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

A triple therapy combination used for Helicobacter pylori eradication. It consists of vonoprazan fumarate (a potassium-competitive acid blocker), furazolidone (an antibiotic), and doxycycline (a tetracycline antibiotic). This combination is being studied as an alternative to traditional proton pump inhibitor-based therapies due to vonoprazan's superior acid suppression capabilities.

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)Bacterial Ribosome

Beyond the preview

Go deeper on vonoprazan fumarate + furazolidone + doxycycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vonoprazan fumarate + furazolidone + doxycycline.

Explore the full profile